ENESTnd 10年分析:尼洛替尼对比伊马替尼一线治疗初诊慢性期CML的长期结局
ENESTnd研究对初诊慢性期CML患者随访≥10年,尼洛替尼(300mg BID或400mg BID)较伊马替尼400mg QD获得更高的累积分子学缓解率和TFR资格率,疾病进展和CML相关死亡更低,但心血管事件累积发生率更高。总体疗效与安全性结果支持尼洛替尼300mg BID作为一线治疗以获得最佳长期结局,尤其针对追求TFR的患者,需结合个体治疗目标评估获益风险。
要点
- 尼洛替尼300mg BID的10年累积MMR为77.7%、MR4.5为61.0%,均高于伊马替尼。
- 尼洛替尼300mg BID的10年TFR资格累积率为48.6%,高于伊马替尼的29.7%。
- 尼洛替尼300mg BID心血管事件累积发生率为16.5%,高于伊马替尼的3.6%。
核心结论
- 尼洛替尼300mg BID一线治疗初诊慢性期CML可获得优于伊马替尼的长期分子学缓解和TFR资格,但心血管事件风险更高,需个体化评估获益风险。
研究设计与样本
- ENESTnd研究为随机对照试验,对初诊慢性期CML患者随访≥10年,比较尼洛替尼300mg BID、400mg BID与伊马替尼400mg QD。
主要发现
- 10年累积MMR率:尼洛替尼300mg BID为77.7%,400mg BID为79.7%,伊马替尼为62.5%。
- 10年累积MR4.5率:尼洛替尼300mg BID为61.0%,400mg BID为61.2%,伊马替尼为39.2%。
- 10年TFR资格累积率:尼洛替尼300mg BID为48.6%,400mg BID为47.3%,伊马替尼为29.7%。
- 估计10年总生存率:尼洛替尼300mg BID为87.6%,400mg BID为90.3%,伊马替尼为88.3%。
- 10年心血管事件累积发生率:尼洛替尼300mg BID为16.5%,400mg BID为23.5%,伊马替尼为3.6%,包括Framingham低风险患者。
关键数值与推荐
- 10年累积MMR:尼洛替尼300mg BID 77.7%、400mg BID 79.7%、伊马替尼62.5%。
- 10年累积MR4.5:尼洛替尼300mg BID 61.0%、400mg BID 61.2%、伊马替尼39.2%。
- 10年TFR资格累积率:尼洛替尼300mg BID 48.6%、400mg BID 47.3%、伊马替尼29.7%。
- 估计10年总生存率:尼洛替尼300mg BID 87.6%、400mg BID 90.3%、伊马替尼88.3%。
- 10年心血管事件累积发生率:尼洛替尼300mg BID 16.5%、400mg BID 23.5%、伊马替尼3.6%。
临床怎么用
- 尼洛替尼300mg BID可作为初诊慢性期CML的一线治疗选择,尤其适用于追求TFR的患者。
- 治疗决策时应结合个体治疗目标,仔细评估尼洛替尼的心血管事件风险与疗效获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free remission (TFR). Cumulative 10-year rates of MMR and MR4.5 were higher with nilotinib (300 mg twice daily [BID], 77.7% and 61.0%, respectively; 400 mg BID, 79.7% and 61.2%, respectively) than with imatinib (400 mg once daily [QD], 62.5% and 39.2%, respectively). Cumulative rates of TFR eligibility at 10 years were higher with nilotinib (300 mg BID, 48.6%; 400 mg BID, 47.3%) vs imatinib (29.7%). Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency of adverse events was similar with nilotinib and imatinib. By 10 years, higher cumulative rates of cardiovascular events were reported with nilotinib (300 mg BID, 16.5%; 400 mg BID, 23.5%) vs imatinib (3.6%), including in Framingham low-risk patients. Overall efficacy and safety results support the use of nilotinib 300 mg BID as frontline therapy for optimal long-term outcomes, especially in patients aiming for TFR. The benefit-risk profile in context of individual treatment goals should be carefully assessed.
引用
- Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021. PMID: 33414482. doi:10.1038/s41375-020-01111-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。